Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Second Quarter Earnings Results
Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2021 second quarter earnings on November 5, 2020, before market open. A conference call is scheduled for the same day at 8:30 a.m. ET, where management will discuss the results. Participants in the U.S. can dial 844-233-9440 or 574-990-1016 internationally, using conference ID 4199894. This announcement is expected to provide insights into the company's financial performance, including potentially key metrics such as revenue and earnings per share.
- None.
- None.
TARRYTOWN, N.Y., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2021 second quarter earnings release on Thursday, November 5, 2020 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
To participate via phone listeners calling from the U.S. and Canada may dial 844-233-9440, or 574-990-1016 internationally, using the conference ID 4199894. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com.
Telephonic replays will be available for approximately one week following completion of the live call and can be accessed at 855-859-2056 within North America, and at 404-537-3406 from outside North America. The conference ID is 4199894.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
irinquiries@prestigebrands.com
FAQ
When will Prestige Consumer Healthcare release its Q2 earnings for fiscal 2021?
What time is the conference call for Prestige's Q2 earnings?
How can I listen to the Prestige Consumer Healthcare earnings call?
Is there a webcast for the earnings call?
